Welcome to our dedicated page for AbbVie SEC filings (Ticker: ABBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AbbVie Inc. filings document formal disclosures for a global pharmaceutical issuer with common stock and multiple senior note series registered on the New York Stock Exchange. Recent Form 8-K reports cover quarterly and annual results, preliminary earnings impacts from acquired IPR&D and milestone expenses, material-event disclosures, material agreements and capital-structure updates.
The company’s filing record also includes debt-financing disclosures for completed senior note offerings and definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items. These documents provide regulatory detail on AbbVie’s operating results, listed securities, governance framework and financing activity.
AbbVie Inc. director Edward J. Rapp reported an acquisition of stock equivalent units tied to AbbVie stock. On 12/31/2025, 147 stock equivalent units were credited at a price of $228.49 per unit, bringing his total directly held derivative securities reported on this form to 28,498 stock equivalent units.
The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are paid in cash generally at age 65 or upon retirement from the board. These stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the reported balance includes units acquired through a dividend reinvestment feature.
AbbVie Inc. reported Q3 2025 results. Net revenues were $15,776 million, up from $14,460 million a year ago, while operating earnings fell to $1,904 million from $3,831 million as the company recorded significant charges. Net earnings were $186 million and diluted EPS was $0.10.
Results reflect acquired IPR&D and milestones expense of $2,680 million in the quarter and intangible asset impairments of $847 million in cost of products sold tied to Resonic and Durysta. Interest expense, net, was $667 million. For the nine months ended September 30, 2025, net revenues were $44,542 million and net earnings were $2,410 million; operating cash flow was $13,812 million.
AbbVie completed or announced portfolio moves: Capstan Therapeutics (cash consideration of $2.1 billion; $1.9 billion recognized in IPR&D), Ichnos Glenmark ISB-2001 license (upfront $700 million), ADARx options (upfront $335 million), Gubra license (upfront $350 million), Nimble Therapeutics acquisition (aggregate $288 million). Subsequent to quarter end, AbbVie acquired Gilgamesh Pharmaceuticals for approximately $900 million upfront. Total equity was a deficit of $2,599 million as of September 30, 2025.
AbbVie Inc. (ABBV) filed an 8-K announcing Q3 2025 results. The company issued a press release for the third quarter ended September 30, 2025, and furnished it with this report.
The press release is included as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition). No financial figures are detailed in this report itself.
AbbVie Inc. filed a Form 8-K to update investors on how acquired in-process research and development (IPR&D) and milestone expenses will affect its 2025 earnings. For the third quarter of 2025, AbbVie expects to record $2.7 billion of acquired IPR&D and milestones expense on a pre-tax basis, which it says will have an unfavorable impact of $1.50 on both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. The company notes that results for the quarter ended September 30, 2025 are still preliminary and may change.
AbbVie reiterates that it does not forecast acquired IPR&D and milestones expense because the timing and occurrence of such transactions are uncertain, and prior 2025 guidance excluded these expenses beyond the second quarter. Including the third quarter 2025 acquired IPR&D and milestones expense, AbbVie now provides a full-year 2025 adjusted diluted earnings per share guidance range of $10.38 to $10.58, and a third quarter 2025 adjusted diluted earnings per share guidance range of $1.74 to $1.78.
Susan E. Quaggin, an AbbVie Inc. (ABBV) director, had 67 stock equivalent units credited to her account on 09/30/2025 at a unit value of $231.54. The filing shows these units are held in a grantor trust and are paid in cash generally at age 65 or upon retirement from the board; they earn returns as if invested in AbbVie stock. The report indicates a post-transaction beneficial ownership balance of 634 shares (including units acquired through a dividend reinvestment feature).
Robert J. Alpern, an AbbVie director, reported a Form 4 disclosing a non‑derivative acquisition on 09/30/2025 of 33 stock equivalent units credited at a per‑unit value of $231.54. The filing states these units are director fees credited to grantor trust accounts established by Abbott Laboratories and AbbVie and that AbbVie account units are payable in cash generally at age 65 or upon retirement from AbbVie’s board. The report shows a total beneficial ownership balance of 10,151 stock equivalent units (including amounts from dividend reinvestment). The Form 4 was signed by an attorney‑in‑fact on 10/02/2025.
AbbVie Inc. reported that it has settled litigation with all generic drug manufacturers that filed abbreviated new drug applications in the United States for generic versions of its upadacitinib tablets, marketed as RINVOQ. Based on these settlement and license agreements, and assuming pediatric exclusivity is granted, AbbVie does not expect any generic upadacitinib tablet products to enter the U.S. market before April 2037, subject to standard acceleration provisions in the agreements.
The company also reiterated that these expectations are forward-looking and could be affected by factors such as intellectual property challenges, litigation outcomes, regulatory changes, and broader business risks described in its prior annual and quarterly reports.
AbbVie Inc. (ABBV) Form 144 notice: An insider proposes to sell 62,755 shares of common stock through Morgan Stanley Smith Barney LLC on 08/22/2025. The shares were acquired the same day via a stock option exercise and paid for in cash. The filing lists an aggregate market value for the proposed sale of $13,231,264.20 and reports 1,766,558,253 shares outstanding for the class. The filer also reported four prior common-stock sales in August 2025 by Richard A. Gonzalez: 61,500 shares on 08/01/2025 (gross proceeds $12,043,268.25), 35,120 shares and 91,600 shares on 08/04/2025 (gross proceeds $6,828,296.22 and $19,208,000.00 respectively), and 90,000 shares on 08/21/2025 (gross proceeds $18,993,947.76). The filer certifies no undisclosed material adverse information and acknowledges legal penalties for false statements.
AbbVie insider sale notice: This Form 144 shows that Richard A. Gonzalez intends to sell 90,000 AbbVie (ABBV) common shares through Morgan Stanley Smith Barney on 08/21/2025 with an aggregate market value of $18,993,947.76. The filing reports Abbies outstanding shares as 1,766,558,253, so the planned sale represents a small fraction of total shares. The 90,000 shares were acquired the same day, 08/21/2025, by stock option exercise and paid for in cash.
The filing also discloses recent insider sales by Richard A. Gonzalez during the past three months: 61,500 shares sold 08/01/2025 for $12,043,268.25; 35,120 shares sold 08/04/2025 for $6,828,296.22; and 91,600 shares sold 08/04/2025 for $19,208,000. The notice includes the standard insider representation that no undisclosed material adverse information is known.
AbbVie EVP and Chief Operations Officer Azita Saleki‑Gerhardt exercised an employee stock option for 42,370 shares of common stock at $54.86 per share, then sold 42,370 shares on August 12, 2025 at a weighted‑average price of about $198.42, based on multiple trades between $198.34 and $198.58 per share. Following these transactions she holds 177,292 AbbVie shares directly, plus indirect interests including 2,647 shares in an AbbVie savings program and 3,873 shares held by her spouse, for which she disclaims beneficial ownership.